IP Library Patent Application 11440809
Patent Application
App. No. 11/440,809

Polyclonal-polyclonal ELISA assay for detecting N-terminus-proBNP

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/440,809
Abstract

A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma. In order to obtain antibodies with specific binding properties for targeted amino acid sequences within human proBNP, recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen. Polyclonal antibodies (PAb) to specific amino acid sequences were subsequently purified from goat serum by sequential affinity purification. Recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified in order to obtain material for use in calibration of a quantitative method for measurement of human NT-proBNP.

Claims (13)

1 . An enzyme linked immunosorbent assay (ELISA) process useful in diagnosing, stratifying, and predicting mortality rate in patients with congestive heart failure comprising:

obtaining isolated polyclonal antibodies specific for an amino acid sequence selected from the group consisting of amino acids 1-25 of Sequence ID No. 1, amino acids 26-51 of sequence ID No. 1, amino acids 52-76 of Sequence ID No. 1, and amino acids 77-108 of Sequence ID No. 1;

selecting a first polyclonal antibody from said group and attaching said polyclonal antibody to a solid support;

reacting a clinical sample suspected of containing immunogenic fragments of NT-proBNP with said isolated polyclonal antibody;

selecting a second polyclonal detector antibody selected as recognizing an amino acid sequence which is separate and distinct from the amino acid sequence recognized by said first polyclonal antibody;

effecting an immunoreaction; and

detecting said immunoreaction.

2 . The assay of claim 1 wherein:

said first polyclonal antibody is selected as being specific to an amino acid sequence consisting of amino acids 26-51 of Sequence ID No. 1 and said second polyclonal antibody is selected as being specific to an amino acid sequence consisting of amino acids 1-25 of Sequence ID No. 1.

3 . The assay of claim 1 wherein:

said first polyclonal antibody is selected as being specific to an amino acid sequence consisting of amino acids 1-25 of Sequence ID No. 1 and said second polyclonal antibody is selected as being specific to an amino acid sequence consisting of amino acids 26-51 of Sequence ID No. 1.

4 . The assay of claim 1 wherein said detection is direct.

5 . The assay of claim 1 wherein said detection is indirect.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2008
From: NANOGEN POINT OF CARE INC.
To: NANOGEN INC.
Reel/Frame 021795/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2008
From: JACKOWSKI, GEORGE; DAVEY, MICHELLE; STANTON, ERIC; KUPCHAK, PETER
To: SYN X PHARMA
Reel/Frame 021766/0056 →
CHANGE OF NAME Recorded Oct 30, 2008
From: SYNX PHARMA INC.
To: NANOGEN POINT OF CARE INC.
Reel/Frame 021766/0352 →
GRANT OF SECURITY INTEREST Recorded Jul 25, 2008
From: NANOGEN, INC.
To: PORTSIDE GROWTH & OPPORTUNITY FUND, AS COLLATERAL AGENT
Reel/Frame 021291/0605 →